INCB 50465

Drug Profile

INCB 50465

Alternative Names: INCB-050465; INCB-50465

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Myelofibrosis
  • Phase I/II B cell lymphoma; Solid tumours
  • Phase Unknown Follicular lymphoma

Most Recent Events

  • 22 Mar 2017 Incyte corporation has patents pending for INCB 050465 in USA, European Union and Japan (Incyte corporation form 10-k, March 2017)
  • 22 Mar 2017 Incyte corporation has patent protection for INCB 050465 in USA, European Union and Japan (Incyte corporation form 10-k, March 2017)
  • 31 Jan 2017 Investigation in Follicular lymphoma in USA (unspecified route) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top